Prelude Therapeutics Q2 EPS $(0.54) Beats $(0.63) Estimate; Cash, Cash Equivalents, And Marketable Securities Of $255M Sufficient To Fund Operations Into 2026
Portfolio Pulse from Benzinga Newsdesk
Prelude Therapeutics reported Q2 losses of $(0.54) per share, beating the analyst consensus estimate of $(0.63) by 14.29%. This is a 6.9% increase over losses from the same period last year. The company's cash, cash equivalents, and marketable securities of $255M are sufficient to fund operations into 2026.
August 04, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prelude Therapeutics reported better than expected Q2 losses and has sufficient funds to operate until 2026.
Prelude Therapeutics reported a smaller than expected loss for Q2, which is positive for the stock. Additionally, the company's strong cash position reduces financial risk and provides stability for the foreseeable future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100